Clinical Trials/NCT05745311

NCT05745311

Not yet recruiting

Phase 2

A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke.

Kunming Pharmaceuticals, Inc.0 sites240 target enrollmentMarch 1, 2023

ConditionsAcute Ischemic Stroke

InterventionsThe KPCXM18 injection Placebo

DrugsThe KPCXM18 injection Placebo

Overview

Phase: Phase 2
Intervention: The KPCXM18 injection
Conditions: Acute Ischemic Stroke
Sponsor: Kunming Pharmaceuticals, Inc.
Enrollment: 240
Primary Endpoint: Change in NIHSS score from baseline at day 10 after administration
Status: Not yet recruiting
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and its PK/PD characteristics in patients.

Registry

clinicaltrials.gov

Start Date

March 1, 2023

End Date

July 30, 2024

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Kunming Pharmaceuticals, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age 18 to 80 years old (including 18 years old and 80 years old), male or female;
•Diagnosed with acute ischemic stroke according to the "Chinese guidelines for the diagnosis and treatment of acute ischemic stroke 2018";
•The time from the last normal behavior to the time of initiation of the drug infusion ≤ 48 hours. For stroke after waking up or when the time of symptom onset cannot be accurately obtained due to aphasia, consciousness disorder, and other reasons, the time of onset should take the last time the patient showed normally as standard;
•The patients who first attacked, or the patients who had a good prognosis after the last attacked ( mRS score was ≤1 before the onset of the disease );
•During the screening period, 4 points ≤ NIHSS score ≤ 24 points, and the sum of NIHSS fifth upper limb and sixth lower limb score ≥2 points;
•The subject or his guardian is aware of the study, and if the subject or his guardian is unable to read, the impartial witness reads the informed consent form and other written materials, witnesses the informed consent, voluntarily participates and signs the written informed consent.

Exclusion Criteria

•Patients with intracranial hemorrhagic diseases confirmed by head CT or MRI: hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc;
•Patients with disturbance of consciousness (NIHSS score Ia ≥2 points);
•Patients who need or have undergone intravenous thrombolysis or endovascular interventional therapy (including endovascular mechanical thrombectomy, intravascular thrombus aspiration, arterial thrombolysis, angioplasty and stenting, etc.) or patients with arteriovenous bridging therapy after this onset;
•Patients with malignant tumors, serious diseases of blood, digestion or other systems or diseases with bleeding tendencies (such as hemophilia, etc.), and the expected survival time is not more than 3 months;
•Patients with a history of major surgery within 1 month before screening;
•Patients with severe hypertension (systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥110 mmHg) that cannot be controlled after treatment;
•Patients with heart rate \< 40 beats/min and/or ventricular rate \> 120 beats/min; Patients with 2nd and 3rd degree heart blocks without pacemakers or other malignant arrhythmias; Patients with acute myocardial infarction, cardiac interventional therapy, or heart failure (grade III and IV according to NYHA) within the past 1 month;
•Patients with severe liver function impairment, or ALT, AST \> 2.0 times the upper limit of normal value (ULN);
•Patients with severe renal impairment, or serum creatinine (Cr) \> 1.5× ULN;
•Patients who have used neuroprotective drugs (including commercially available edaravone, edaravone and dexborneol, nimodipine, gangliosides, piracetam, oxiracetam, butylphthalide, etc.) after the onset of this illness, as well as other traditional Chinese medicine labels containing the effect of treating acute ischemic stroke (cerebral infarction);

Arms & Interventions

low-dose group （The KPCXM18 injection）

Intravenous infusion of 20 mg twice daily at intervals of 12±2 hours for 10 days.

Intervention: The KPCXM18 injection

middle-dose group （The KPCXM18 injection）

Intravenous infusion of 60 mg twice daily at intervals of 12±2 hours for 10 days.

Intervention: The KPCXM18 injection

high-dose group （The KPCXM18 injection）

Intravenous infusion of 100 mg twice daily at intervals of 12±2 hours for 10 days.

Intervention: The KPCXM18 injection

Placebo

Intravenous infusion twice a day with an interval of 12±2 hours for 10 days.

Intervention: Placebo

Outcomes

Primary Outcomes

Change in NIHSS score from baseline at day 10 after administration

Time Frame: day 10

The National Institute of Health stroke scale(NIHSS) score ranging from 0-42. Higher score indicates worse function.

Secondary Outcomes

Proportion of subjects with mRS score ≤ 1 at day 90±7 after administration(day 90±7)
Change in BI score from baseline at day 90±7 after administration(day 90±7)
Change in EQ-5D score from baseline at day 90±7 after administration(day 90±7)
Changes in NIHSS score from baseline on days 30±3 and 90±7 after administration(days 30±3 and 90±7)
Changes in mRS score from baseline on days 30±3 and 90±7 after administration(days 30±3 and 90±7)
The proportion of subjects whose NIHSS score improved by ≥4 points at days 10, 30±3 and 90±7 after administration(days 10, 30±3 and 90±7)
Proportion of subjects with recurrence of stroke within 90±7 days after administration(within 90±7 days)
Changes in serum biomarkers (TNF-α, MMP9, CHE, IL-10, S100-β) from baseline on day 7 after administration(day 7)